Back Back

2022 ASCO Annual Meeting

June 3-7, 2022; Chicago, Illinois
Review slidesets and expert analyses of key data from the 2022 Clinical Oncology Annual Scientific Meeting!

Share

Program Content

10 Capsule Summary Slidesets

Activities

RELATIVITY-047: Subgroup Analysis
RELATIVITY-047: OS and ORR by Key Subgroups in Patients With Advanced Melanoma Receiving First-line Relatlimab + Nivolumab vs Nivolumab Alone
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
NeoTrio
NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAFV600-Mutant Stage III Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
SWOG 1512
SWOG 1512: Phase II Study of Neoadjuvant Pembrolizumab in Patients With Resectable Desmoplastic Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
KEYNOTE-716 Update
KEYNOTE-716: Update of the Phase III Trial of Adjuvant Pembrolizumab vs Placebo in Stage IIB/IIC Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
Tebentafusp + Anti–PD-L1: Cutaneous Melanoma
Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
PRADO
PRADO: Phase II Trial of Response-Directed Surgery and Adjuvant Therapy Following Neoadjuvant Ipilimumab and Nivolumab in Stage III Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
CAM/APA/TMZ in Acral Melanoma
First-line Camrelizumab, Apatinib, and Temozolomide in Advanced Acral Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
TRICOTEL
TRICOTEL: Phase II Study of Atezolizumab, Cobimetinib, and Vemurafenib in BRAFV600-Mutated Melanoma With CNS Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
CheckMate 067: 7.5-Yr Update
CheckMate 067: Long-term Survival and HRQoL With First-line Nivolumab ± Ipilimumab in Advanced Melanoma at 7.5-Yr Follow-up
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity
AMBER Parts 1C and 1E
AMBER Parts 1C and 1E: Phase I Trial of Cobolimab, an Anti–TIM-3 mAb, Plus Dostarlimab in Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2022

Expires: June 19, 2023

View Activity

Activities

ASCO 2022: Key Skin Cancer Studies
Key Studies in Skin Cancer: Independent Conference Coverage of the 2022 ASCO Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 29, 2022

Expires: August 28, 2023

22 Capsule Summary Slidesets

Activities

Glofitamab in R/R DLBCL
Pivotal Phase II Trial of Glofitamab in R/R DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

View Activity
Ponatinib/Blinatumomab in ALL
Phase II Trial of Ponatinib + Blinatumomab in Adults With Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
ROSEWOOD
ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
ELEVATE-TN: 5-Yr Update
ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
SHINE
SHINE: First-line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
MajesTEC-1 Update
MajesTEC-1: Update From Phase I/II Trial of the BCMA x CD3 Bispecific Antibody Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
ECHELON-1 OS Analysis
ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
ASCEMBL 96-Wk Update
ASCEMBL: 96-Wk Update of Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2 TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
ASCEND: 4-Yr Update
ASCEND: 4-Yr Follow-up Analysis of Acalabrutinib vs Rituximab + Idelalisib or Bendamustine in Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
ATLAS: Post-ASCT KRd
Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
GC012F Phase I
First-in-Human Study of GC012F: BCMA/CD19 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
Magrolimab + Aza for AML
Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
DETERMINATION
DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CAPTIVATE: FD Cohort 3-Yr Update
CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
IDHENTIFY by <i>IDH2</i> Variant
Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
Dual Anti–PD-1/Anti–LAG-3 in cHL
Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
Zilovertamab + Ibr in MCL or CLL
Phase I/II Trial of Zilovertamab, an Anti-ROR1 Antibody, Plus Ibrutinib in MCL or CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
EPCORE NHL-2: R/R FL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R2 in R/R Follicular Lymphoma: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity
EPCORE NHL-2: DLBCL
Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity
Crenolanib + 7+3 in AML
Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

View Activity
Pre-MEASURE: MRD in AML pre-alloHCT
Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

View Activity
Mini-HCVD + INO ± Blina in B-ALL
Mini-HyperCVD + Inotuzumab Ozogamicin ± Blinatumomab in Older Adults With Newly Diagnosed Ph-Negative B-Cell ALL: Updated Phase II Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022
View Activity

Activities

Hematologic Malignancies Highlights: ASCO 2022
Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2022 ASCO Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2022

Expires: September 12, 2023

10 Capsule Summary Slidesets

Activities

HIMALAYA: PRO Analysis
HIMALAYA: Patient-Reported Outcomes for Patients With Unresectable Hepatocellular Carcinoma Receiving Durvalumab ± Tremelimumab
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
TOPAZ-1: PRO Data
TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
PARADIGM
PARADIGM: Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6 as First-line Treatment for mCRC With Wild-Type RAS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
TRIPLETE
TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
CheckMate 142: 5-Yr Update
CheckMate 142: 5-Yr Follow-up With Nivolumab ± Ipilimumab for MSI-H/dMMR Metastatic CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
HERB: T-DXd for BTC
HERB: Single-Arm Phase II Trial of Trastuzumab Deruxtecan for Unresectable or Recurrent HER2-Expressing Biliary Tract Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
CONKO-007: CRT vs CT
CONKO-007: Chemoradiotherapy vs Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CAIRO5
CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CheckMate 648: Expanded Analysis
CheckMate 648: Expanded Analysis of First-line Nivolumab + CT vs Nivolumab/Ipilimumab vs CT in Advanced Esophageal Squamous Cell Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
Dostarlimab in dMMR Rectal Cancer
Phase II Study of Dostarlimab in Locally Advanced, Mismatch Repair–Deficient Rectal Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2022

Expires: June 13, 2023

View Activity

Activities

ASCO 2022 GI Cancers
Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 31, 2022

Expires: August 30, 2023

14 Capsule Summary Slidesets

Activities

DESTINY-Breast04
DESTINY-Breast04: Trastuzumab Deruxtecan vs Physician’s Choice of Chemotherapy for Previously Treated HER2-Low Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

View Activity
TROPiCS-02
TROPiCS-02: Phase III Trial of Sacituzumab Govitecan vs Physician’s Choice Treatment for HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

View Activity
KEYNOTE-826: Subgroup Analysis
KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
MAINTAIN
MAINTAIN: Phase II Study of Switching ET ± Ribociclib for HR+/HER2- Metastatic Breast Cancer After Failure of Previous ET + CDK4/6i
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
FAKTION Update
FAKTION: Updated and Expanded Analysis of Fulvestrant + Capivasertib or Placebo After Aromatase Inhibitor Therapy in ER+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
innovaTV 205
ENGOT Cx8/GOG 3024/innovaTV 205: Interim Phase II Results With Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
PALOMA-2: Final OS
PALOMA-2 Final OS Analysis: Addition of Palbociclib to Frontline Letrozole in Postmenopausal ER+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
GARNET: Dostarlimab in EC
GARNET: Update From Phase I Trial of Dostarlimab in Patients With Advanced or Recurrent dMMR/MSI-H or pMMR/MSS Endometrial Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
ORZORA OS Results
ORZORA: OS Results With Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer With a BRCA Mutation or Other HRR Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
ATHENA-MONO
ATHENA-MONO: Phase III Trial of Maintenance Rucaparib vs Placebo After First-line Platinum-Based Chemotherapy in Advanced Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2022

Expires: June 13, 2023

View Activity
KEYNOTE-522: EFS by RCB
KEYNOTE-522: Exploratory Analysis of EFS by Residual Cancer Burden With Neoadjuvant Pembrolizumab + Chemotherapy for Early TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2022

Expires: June 13, 2023

View Activity
Relacorilant in PROC
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer: OS Analysis From a Randomized Phase II Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
LUMINA
LUMINA: Local Recurrence With Omission of Radiotherapy After Breast-Conserving Surgery in T1N0 Luminal A Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2022

Expires: June 14, 2023

View Activity
MITO23
MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2022

Expires: June 16, 2023

View Activity

Activities

ASCO 2022: Key Studies
An Expert’s Guide to ASCO 2022: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2022

ASCO 2022 Breast/Gyn
Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: August 17, 2022

Expires: August 16, 2023

13 Capsule Summary Slidesets

Activities

KRYSTAL-1
KRYSTAL-1 Trial of Adagrasib in Patients With Previously Treated Advanced KRASG12C-Mutated NSCLC: Analysis of Registrational Phase II Cohort
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
TACTI-002
Phase II TACTI-002 Trial: Updated Results With Eftilagimod Alpha Plus Pembrolizumab as First-line Therapy in Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2022

Expires: June 06, 2023

View Activity
ATLANTIS Lurbinectedin Monotherapy
ATLANTIS: Analysis of Outcomes With Single-Agent Lurbinectedin After Lurbinectedin + Doxorubicin in Relapsed SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

View Activity
SKYSCRAPER-02
SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
OPAL: 1L Osi + CT in NSCLC
OPAL: Phase II Trial of First-line Osimertinib Plus Platinum-Based Doublet Chemotherapy in EGFR-Mutated Advanced NSCLC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
Patritumab Deruxtecan in Adv NSCLC
Phase I Trial of Patritumab Deruxtecan for Previously Treated Advanced NSCLC Without EGFR Activating Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2022

Expires: June 08, 2023

View Activity
CLN-081: <i>EGFR</i> ex20ins+ NSCLC
Updated Results of a Phase I/IIa Trial of CLN-081, a Selective EGFR TKI, in Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CheckMate 816 Post Hoc EFS Analysis
CheckMate 816: Association of Pathologic Regression With EFS for Neoadjuvant Nivolumab + CT in Resectable NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
CHRYSALIS: Ami for <i>MET</i>ex14+ NSCLC
CHRYSALIS: Updated Phase I Trial Results of Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
NADIM II: Neoadj Nivo + CT
NADIM II: Phase II Trial of Neoadjuvant Nivolumab + Chemotherapy vs Chemotherapy in Resectable Stage IIIA/B NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2022

Expires: June 09, 2023

View Activity
KRYSTAL-1 CNS Cohort
KRYSTAL-1: Phase Ib Report of Adagrasib Activity in Patients With KRAS G12C–Mutated NSCLC and Active, Untreated CNS Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2022

Expires: June 12, 2023

View Activity
CHRYSALIS-2 Update
CHRYSALIS-2: Update of Amivantamab + Lazertinib in EGFR-Mutant NSCLC After Progression on Osimertinib and Chemotherapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2022

Expires: June 13, 2023

View Activity
ATEZO-BRAIN Update
Phase II ATEZO-BRAIN: Updated Results With Atezolizumab + Carboplatin/Pemetrexed in Advanced Nonsquamous NSCLC With Untreated Brain Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 16, 2022

Expires: June 15, 2023

View Activity

Activities

Lung Cancer Highlights: ASCO 2022
Key Studies in Lung Cancer: Independent Conference Coverage of ASCO 2022
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: September 01, 2022

Expires: August 31, 2023

Faculty

cover img faculity

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

cover img faculity

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

cover img faculity

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

cover img faculity

Angeles Alvarez Secord, MD, MHSc

Director of Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Division of Gynecologic Oncology
Department of OB/GYN
Durham, North Carolina

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

cover img faculity

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Hussein Tawbi, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab